For 81 years, this industry was in a hazy legal status. Burdened by regulations, and legal in some states while illegal in others.
This advertisement is from DailyWealth, a free e-letter.
You can unsubscribe here but you will no longer receive DailyWealth.
Daily Wealth

Editor's note: While we haven't done much research into CBD oil, it's been making headlines recently as a potential treatment for several illnesses. Our research team will dive into this topic more this year, but in the meantime, we recommend checking out this video from our friends at Casey Research to understand more about potential opportunities in this market.


Dear Reader, 

See this plant here?

Fake Pot Plant

It looks like a marijuana plant. But it's not.

And while there's been a lot of buzz about marijuana making millionaires and throwing off mega-gains of...

1,240%... and even 2,590%... on investor's money...

This plant you're seeing is what some might call "fake pot" or "no buzz marijuana."

And my research shows it'll spin off bigger gains than legal pot.

For 81 years, this industry was in a hazy legal status. Burdened by regulations, and legal in some states while illegal in others. This held down massive growth potential.

But thanks to federal statute 115-661, which President Trump just signed into law...

It'll unleash a tsunami of money that'll explode 40 times in value.

That's why billionaire investors like Warren Buffett, Bill Gates, Leon Cooperman, and Peter Thiel – the founder of PayPal – are circling this industry.

Corporations are too... Constellation Brands (the maker of Corona beer), Microsoft, and Coca-Cola are piling in.

Hedge funds like Poseidon, Tribeca Global Natural Resources, and Tiger Global Management are streaming into this space.

So, why would anyone be interested in "fake pot"?

Put simply, most people want health benefits without getting stoned. 

And the health benefits of "fake pot" are truly miraculous!

Some patients claim it can kill certain cancers... it alleviates multiple sclerosis, arthritis, Parkinson's, and Crohn's disease. It's even shown to offset diabetes, soothe pain and depression, and help insomniacs sleep like a baby.

A recent survey in Forbes found eighty percent of people who use it reported it was "very or extremely effective."

Rolling Stone magazine calls it "The drug of the future."

I want to see if these claims are true.

So... on camera, I'm going to demonstrate if "fake pot" will work a miracle for me.

Watch my demo here.

Sincerely,

Nick Giambruno.
Chief Analyst, Crisis Investing

P.S. Inc. magazine says,

Inc Magazine Quote

More millionaires will be made by this industry than legal pot. And we found the one stock we believe gives you the best shot at making a fortune.

CLICK HERE to see how to ride this 40X wave.



All contents of this e-mail are copyright 2019 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.

DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.

You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to info@stansberrycustomerservice.com.

To unsubscribe from this mailing, click here: Unsubscribe